Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial
- 27 July 2024
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 189, 90-97
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Recent advances in using folate receptor 1 (FOLR1) for cancer diagnosis and treatment, with an emphasis on cancers that affect womenLife Sciences, 2023
- Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trialThe Lancet, 2021
- Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD IAnnals of Oncology, 2021
- Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trialsCancer, 2020
- Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patientsCancer Medicine, 2019
- Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansineGynecologic Oncology, 2017
- Revisiting GM-CSF as an adjuvant for therapeutic vaccinesCellular & Molecular Immunology, 2017
- Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expressionInternational Journal of Cancer, 2015
- A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumorsInvestigational New Drugs, 2014
- Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA–MORAb-003Nuclear Medicine and Biology, 2008